A new mucosal vaccine to protect against tuberculosis
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis
This study is testing a new type of vaccine for tuberculosis that uses tiny droplets to boost your immune system, especially in your lungs, and it's looking for people to help find out if it can offer better protection against tough-to-treat strains of the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10757098 on NIH RePORTER |
What this research studies
This research focuses on developing a novel mucosal vaccine that targets tuberculosis, a disease caused by Mycobacterium tuberculosis. The approach involves using nanoemulsions to enhance the immune response, specifically by inducing T helper type 17 (Th17) cells, which are crucial for fighting off the infection. The study aims to understand how these vaccines can effectively stimulate mucosal immunity in the lungs, providing better protection compared to traditional vaccines. Participants may receive this innovative vaccine to help combat the growing issue of drug-resistant tuberculosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are at risk of tuberculosis or have been exposed to the disease.
Not a fit: Patients who are currently infected with active tuberculosis or those with severe immunocompromised conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that significantly reduces the incidence of tuberculosis and its drug-resistant forms.
How similar studies have performed: Previous research has shown success with mucosal vaccines in other diseases, indicating potential for this novel approach in tuberculosis prevention.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Khader, Shabaana a. — University of Chicago
- Study coordinator: Khader, Shabaana a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.